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 Chronic kidney disease (CKD) confers 
adverse outcomes, particularly increased 
cardiovascular events, premature cardio-
vascular death, and chronic kidney 
failure. 1 Clinical practice guideline (CPG) 
implementation is the most promising way 
to improve care, leading to better out-
comes. Th e fi rst Kidney Disease Outcomes 
Quality Initiative (K / DOQI) CPG for CKD 
has achieved an extraordinary success in 
broad dissemination over a relatively short 
implementation since its publication in 
2002, 1 providing uniform terminology for 
clinicians of every type to defi ne CKD and 
stratify it into stages and promoting the 
remarkable adoption of estimated glomer-
ular fi ltration rate (eGFR) reporting world-
wide. However, the process of optimizing 
CKD care is only just beginning. Th ere is 
little agreement among practitioners in a 
number of pivotal areas, including the 
defi nition of CKD (particularly for the eld-
erly with eGFR of 45 – 60  ml / min per 1.73  m 2 
in the absence of albuminuria), the key 
elements of primary-care management of 
stages 1 – 3 CKD, the indications for neph-
rology consultation, 2 and the scope of the 
respective roles and responsibilities of the 
primary-care physician and the specialist 
following consultation. In the absence of 
consensus in the community, these clinical 
management issues are being interpreted 
at the point of care to a greater degree than 
in longer-established chronic diseases such 
as diabetes and cardiovascular disease. 
Thus, CPG implementation in CKD is 
largely a subjective local process, making 
the systematic assessment of implementa-
tion challenging. Clinical decision support 
is the implementation method of the future 
to bridge the gap between the evidence 
synthesized by CPGs and patient care 
delivered through the electronic health 
record in a cyclical process ( Figure 1 ). 
 Reporting of eGFR and primary care 
 Making kidney-function results directly 
accessible to the clinician is an important 
step in CKD detection and management. 
Kagoma and colleagues 3 (this issue) eval-
uate the implementation of one of the key 
recommendations of the fi rst CKD guide-
line: to assess kidney function with eGFR 
in routine clinical practice, reserving 
24 – h urine creatinine clearance collec-
tions for confirmatory testing. 1 These 
experienced health-service researchers 
use the monthly prevalence of 24 – h urine 
collections in an adult population of more 
than 8 million patients in the province of 
Ontario, Canada, from August 1999 to 
July 2009 to investigate the impact of two 
major interventions: the publication of the 
K / DOQI CKD CPG in February 2002, 
and the introduction of eGFR reporting 
in all outpatient laboratories in January 
2006. Th e authors assume a 3-month lag 
period following each of the two events to 
assess variation based on previous publi-
cations. 4,5 Each eGFR value, based on the 
Modification of Diet in Renal Disease 
(MDRD) Study equation, was accompa-
nied by one of fi ve corresponding prompts 
relating the level of kidney function to 
CKD. For example, results between 30 and 
60  ml / min per 1.73  m 2 were followed by: 
 ‘ consistent with moderate chronic kidney 
disease if result confirmed by repeat 
assessment, with persistence for 3 months 
or more. ’ 4 Th is form of clinical decision 
support assists interpretation with direct 
incorporation into the clinical workfl ow 
for each laboratory result. Th e study is 
well designed, and the methods are rigor-
ous. Th e data capture for this large popu-
lation is impressively comprehensive, 
feasible in part by virtue of universal 
health care with a single federal payer. Th e 
results from Canada ’ s most highly popu-
lated province show no signifi cant change 
following the publication of the K / DOQI 
CKD guideline, but a 23.5 % reduction in 
24-h urine collections aft er eGFR report-
ing with prompts, from 44.6 to 34.1 per 
100,000 population, which remained 
signifi cant aft er adjustment for sex and 
age ( P  <  0.0001). The obvious benefits 
are improved patient convenience, and 
increased accuracy of kidney-function 
assessment for clinical practice using 
eGFR rather than creatinine clearance. 
The estimated cost benefit was small, 
 $ 5651 per month in reduced laboratory 
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fees for 24-h urine testing, based on a per-
test cost of  $ 10.35. Th e inability to distin-
guish the impact of eGFR reporting from 
the impact of the prompt is worth noting 
in addition to the comprehensive discus-
sion of limitations by the authors. The 
eGFR reporting may not have infl uenced 
care in the absence of the kernel of educa-
tional information delivered by the 
prompt. Th ese compelling fi ndings should 
inspire ongoing rigorous implementation 
following future CPG publication, espe-
cially using clinical decision support. 
 Other aspects of primary care assessed 
in the literature following eGFR reporting 
include detection of CKD, achievement of 
target blood pressure, use of renin – angi-
otensin system (RAS) blockers (angi-
otensin-converting enzyme inhibitors and 
angiotensin receptor blockers), avoidance 
of nephrotoxins, drug prescription that 
considers the level of kidney function, and 
implications of a false-positive CKD diag-
nosis. An outpatient study by Wyatt  et al. 
from the US Veterans Affairs Medical 
Center revealed small but significant 
improvements in CKD detection using 
administrative data collection for diagno-
sis codes before and aft er reporting (14.6 
to 21.5 % ) and achievement of blood pres-
sure goal (32.9 to 34.4 % ). 6 Although the 
comparison between detected and unde-
tected CKD did not infl uence the achieve-
ment of target blood pressure, the use of 
the appropriate CKD diagnostic code was 
signifi cantly associated with urinary pro-
tein testing (39.8 % to 54.2 % ). Th ree of 
four studies demonstrated small but sta-
tistically significant increases in RAS 
blockade use following reporting, from 
1.9 to 6 % . 5 – 7 Th e authors of the negative 
study speculated high baseline rates of 
RAS blocker use as a possible explana-
tion. 5 Studies of patient safety risk in CKD 
care and eGFR reporting have been lim-
ited mostly to single academic centers. 7,8 
One study showed no change in nonster-
oidal anti-infl ammatory drug prescription 
rates, 7 while a systematic review of drug 
prescribing practices that considered the 
level of kidney function using clinical 
decision support showed promise overall, 
with the limitation of heterogeneous 
design across studies. 8 Th e reduction in 
quality-adjusted life years associated 
with a false-positive CKD diagnosis was 
considered by one interesting study that 
used Monte Carlo microsimulations in 
the transitions between six conditions: 
normal, false-positive CKD, true-posi-
tive or detected CKD, undetected CKD, 
chronic kidney failure, and death. 9 Th e 
assessment of the cost-eff ectiveness of 
eGFR reporting versus serum creatinine 
reporting by the authors depends on the 
accuracy of the model. Th e assumption 
of one out patient nephrology consul-
tation for all detected and false-posi tive 
CKD may not be realistic. Still, the poten-
tial negative consequences of the patient ’ s 
being labeled with CKD could be 
addressed by the subsequent refi nement 
of the CKD defi nition and / or stratifi ca-
tion in the CPG, as well as through ongo-
ing investigation. 
 Reporting of eGFR and nephrology care 
 Th e eff ects of eGFR reporting on nephrol-
ogy consultation may not be the best met-
ric at this juncture in the absence of 
consensus, 2,7 despite comprehensive 
indications from CPGs. 1,10 A recent sys-
tematic review of the impact of eGFR 
reporting with and without prompts dem-
onstrated an overall increase in nephrol-
ogy consultations in the range of 13 % to 
270 % from 13 of 16 studies. 7 Most studies 
also showed a change in the distribution 
of patients, including more elderly and 
women, as would be expected on the basis 
of the variables of the MDRD Study equa-
tion. In the publications that provided 
data, there was a trend for a decrease in 
stage 1 and 2 consultations with increases 
in stages 3 – 5. 7 Whether or not this is seen 
as a welcome shift  refl ects the subjectivity 
in evaluation, as supported by the variabil-
ity in the definition of an appropriate 
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 Figure 1  |  The cycle of development, publication, and implementation of clinical practice 
guidelines. Implementation or translation into practice should contribute to the development 
of a subsequent guideline, primarily through health services research. Clinical decision support 
is shown as the implementation method that bridges the gap between the evidence synthesized 
by clinical practice guidelines and patient care delivered through the electronic health record. 
The three major components of information technology in health care are shown: the personal 
health record, the electronic health record, and the population health record. The arrows 
represent the flow of information. The arrow between the patient and the personal health record 
is mostly in the direction of the patient, as patient input into the electronic health record is 
currently limited. 
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 Th ere continues to be intense interest in 
furthering our understanding of the cel-
lular and molecular mechanisms underly-
ing acute kidney injury (AKI) through the 
consult. Studies were heterogeneous with 
regard to the predefi ned use of appropriate 
nephrology consultation indications; one 
study used discharge from nephrology 
care within one year of consultation as 
the defi nition of an inappropriate use of 
resources. 7 Two studies evaluated changes 
in the timing of referral relative 
to the onset of chronic kidney failure 
following reporting, but the use of signi-
ficantly different definitions of early 
and late consultation complicated the 
assessment. 7 
 Assessment of the future impact of 
eGFR reporting 
 Th ese preliminary studies are encouraging 
in the overall trend for a benefi t of eGFR 
reporting. Data are needed on the impact 
of reporting on patient and public aware-
ness of CKD and its risk factors and out-
comes. 10 Evaluation of the impact of 
reporting will be essential for the refi ne-
ment of methods of estimating GFR, such 
as the CKD Epidemiology Collaboration 
(CKD-EPI) 2009 creatinine equation and 
the 2012 CKD-EPI cystatin C equation. It 
will also be important to investigate patient 
safety, but the metrics will need to be more 
precisely defi ned. What is the impact of 
eGFR reporting on the timing of dialysis 
initiation? Will there be an infl uence of 
reporting when enough time has elapsed 
to accrue adequate hard end points for car-
diovascular events, onset of chronic kidney 
failure, and mortality? Future studies of 
eGFR reporting should further explore the 
impact of the prompt as a form of clinical 
decision support. Th ere is advance notice 
to consider the implementation before 
publication of an updated CKD CPG 
anticipated in 2012 from Kidney Disease: 
Improving Global Outcomes and the cor-
responding K / DOQI US Commentary. 
Th is will provide an opportunity to reframe 
the discussion regarding the controver sies 
and adoption challenges for routine pri-
mary and nephrology CKD care in a 
second cycle of development, publication, 
and implementation. 
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 Double-edged sword: a p53 
regulator mediates both 
harmful and beneficial effects in 
experimental acute kidney injury 
 Bairbre A.  McNicholas 1 and  Matthew D.  Griffin 1 
 Acute kidney injury triggers activation of innate immune responses and 
of proapoptotic programs such as the p53 pathway. Mulay  et al. examine 
the effects of blocking murine double minute-2 (mdm2), a negative 
regulator of p53, using a novel chemotherapeutic agent, nutlin-3a, in 
mouse ischemia – reperfusion injury. Their results indicate that mdm2 
promotes renal regeneration by limiting p53-mediated apoptosis but 
also enhances early inflammation by facilitating DNA binding of nuclear 
factor-  B independently of p53. 
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use of animal models. 1 Although attempts 
at translation of laboratory research fi nd-
ings to patient populations with AKI have 
yet to yield dramatic clinical benefits, 
there is now a clearer appreciation of the 
complexity of this challenge. 1 Th ere is also 
an emerging consensus that robust pre-
ventative or therapeutic interventions may 
require the manipulation of multiple path-
ways to renal injury — either simultane-
ously or at diff erent stages of the process. 1 
Two mechanisms of injury that may be of 
specific interest in this regard are the 
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